Record Q4 revenue growth of 23% was primarily volume-driven, supported by the highest number of MACI implants and implanting surgeons since the product's 2017 launch. The MACI Arthro technique has successfully accelerated growth in the small condyle defect segment, which historically lagged but became a top growth driver in 2025. Surgeons trained in MACI Arthro demonstrate higher biopsy and implant growth rates, with even higher conversion rates observed once they complete their first Arthro case. M ...

上市程序（主要阶段） 赴纳斯达克上市通常需经历以下核心阶段，整个过程可能耗时6至9个月。 美国纳斯达克上市条件根据公司规模与发展阶段分为三个层级（全球精选市场、全球市场、资本市场），各层级有不同的财务、流动性与公司治理标准； 上市程序主要包括筹备、申请审核、路演定价、发行上市等阶段。纳斯达克151-0151-3603丘-老-师 上市条件（基于三层市场结构） 纳斯达克根据企业规模与财务状况，设立了全球精选市场（要求最高）、全球市场（中等要求）和资本市场（要求最低）三个上市层级。企业需满足所选 层级的特定标准，并符合共同的流动性及公司治理要求。1 赴美纳斯达克上市为例，详细介绍美国IPO流程 全球精选市场 (Global Select Market) 财务标准（满足其一即可）：通常要求较高的收入、现金流、市值或资产规模。例如，收入标准要求前三个会计年度税前收入总和达到1100万美元 且每年盈利。 全球市场 (Global Market) 财务标准（满足其一即可）：包括收入标准（如过去一年或三年中的两年税前收入达到100万美元）、权益标准、市值标准或资产标准。注意：根据 美国证券交易委员会（SEC）2025年12月 ...

Company Performance - Emergent Biosolutions (EBS) shares have increased by 39.7% over the past month, reaching a new 52-week high of $13.41 [1] - The stock has gained 34.3% since the beginning of the year, outperforming the Zacks Medical sector's 4.3% and the Zacks Medical - Biomedical and Genetics industry's 12% returns [1] Earnings and Valuation - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters [2] - In the latest earnings report on October 29, 2025, EBS reported an EPS of $1.06, significantly surpassing the consensus estimate of -$0.12, and beat the revenue estimate by 20.88% [2] - EBS currently trades at 10.8X current fiscal year EPS estimates, below the peer industry average of 18.3X, and at 6.7X trailing cash flow compared to the peer group's average of 16.2X, indicating strong value metrics [6] Style and Zacks Rank - Emergent Biosolutions has a Value Score of A, a Growth Score of D, and a Momentum Score of C, resulting in a VGM Score of B [5] - The stock holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, making it a favorable choice for investors [7][8] Industry Context - The Medical - Biomedical and Genetics industry is positioned in the top 39% of all industries, suggesting favorable conditions for both EBS and its peers [11]

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that began in early April, reaching new all-time highs in the third quarter. The Conestoga Micro-Cap Composite returned 11.7% net-of-fees in the third quarter, compared to the Russell Microcap Growth Index’s return of 19.9%. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2 ...

Company Performance - Wave Life Sciences reported a quarterly loss of $0.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.29, and compared to a loss of $0.25 per share a year ago, indicating a negative earnings surprise of -6.90% [1] - The company posted revenues of $8.7 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31.16%, and down from $19.69 million in the same quarter last year [2] - Over the last four quarters, Wave Life Sciences has surpassed consensus EPS estimates only once and has also topped consensus revenue estimates just once [2] Stock Performance - Wave Life Sciences shares have declined approximately 32.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Wave Life Sciences is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $14.5 million, and for the current fiscal year, it is -$1.12 on revenues of $49.27 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Wave Life Sciences operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable industry environment [8]

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.84%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.16 per share when it actually produced earnings of $1.26, delivering a surprise of 8.62%.Over the last four ...

Group 1 - Travere Therapeutics reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.55, and improved from a loss of $1.76 per share a year ago, representing an earnings surprise of 14.55% [1] - The company posted revenues of $81.73 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3%, and showing significant growth from year-ago revenues of $41.37 million [2] - Travere shares have increased by approximately 19.5% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] Group 2 - The earnings outlook for Travere is uncertain, with current consensus EPS estimates at -$0.45 for the coming quarter and -$1.47 for the current fiscal year, alongside revenues of $83.04 million and $356.83 million respectively [7] - The Zacks Rank for Travere is currently 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions [6] - The Medical - Biomedical and Genetics industry, to which Travere belongs, is currently in the top 32% of Zacks industries, suggesting a favorable environment for stocks within this sector [8]

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the presentatio ...